Teva Pharma (TEVA) Tops Q4 EPS by 2c; Reaffirms

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Teva Pharma (TEVA) Tops Q4 EPS by 2c; Reaffirms

RBC Capital Reiterates Outperform Rating and $42 PT on Teva Pharmaceuticals (TEVA) Following 4Q Results

February 14, 2017 8:47 AM EST

RBC Capital Markets analyst Randall Stanicky reiterates Outperform rating and $42 price target on Teva Pharmaceuticals Industries (NYSE: TEVA), suggesting strategic questions remain, despite the company reporting 2016 fourth quarter results above consensus.

Stanicky comments, "TEVA reported 4Q above Street expectations and reaffirmed 2017... More

Teva Pharma (TEVA) PT Lowered to $40 at Maxim Group

February 13, 2017 1:14 PM EST

Maxim Group lowered its price target on Teva Pharma (NYSE: TEVA) to $40.00 (from $41.00) while maintaining a Hold rating following results this morning.

Analyst Gabrielle Zhou commented, "This morning, Teva reported 4Q16 and full year results; total quarterly revenues were $6.5B, up 16.7% sequentially. Revenues... More